RISFAX October 20, 2017日本語
- Japan Pharmaceutical Manufacturers Association (JPMA): “Strict warning” to Bayer Yakuhin for the violation of side effect reporting obligation
- Advanced medical care subcommittee: Transplantation of diseased kidneys “appropriate” on the conditions of strict case entry, etc.
- First Committee on Drugs on November 2 to deliberate pediatric indication for NEXIUM, a new formulation, too
- UK AstraZeneca: “Durvalumab” for Stage III lung cancer, NDA accepted in US
- s.maX: “CANALIA COMBINATION TABLETS” at the top in GP market, appealing advantage in terms of NHI price
- KENEI Pharmaceutical: Term ended August 2017, ethical and OTC drugs deliver good performance, with sales up 5.7%